[CHRS] Coherus BioSciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 28.05 Change: 0.05 (0.18%)
Ext. hours: Change: 0 (0%)

chart CHRS

Refresh chart

Strongest Trends Summary For CHRS

CHRS is in the medium-term down -38% in 8 months. In the long-term down -71% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -63.81% Sales Growth - Q/Q-10.52% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-50.75% ROE-203.75% ROI
Current Ratio2.77 Quick Ratio Long Term Debt/Equity Debt Ratio1.36
Gross Margin Operating Margin-245.92% Net Profit Margin-274.14% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-730 K Cash From Investing Activities-1.31 M Cash From Operating Activities-33.06 M Gross Profit
Net Profit-40.73 M Operating Profit-36.75 M Total Assets153.15 M Total Current Assets143.9 M
Total Current Liabilities51.91 M Total Debt Total Liabilities115 M Total Revenue5.81 M
Technical Data
High 52 week20.25 Low 52 week8.38 Last close11.51 Last change-5.58%
RSI67.5 Average true range0.79 Beta1.62 Volume340.72 K
Simple moving average 20 days14.38% Simple moving average 50 days8.05% Simple moving average 200 days-19.82%
Performance Data
Performance Week-0.26% Performance Month18.29% Performance Quart-11.8% Performance Half-22.75%
Performance Year-8.65% Performance Year-to-date27.18% Volatility daily5.53% Volatility weekly12.36%
Volatility monthly25.34% Volatility yearly87.76% Relative Volume232.26% Average Volume797.02 K
New High New Low

News

2019-03-19 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-03-19 08:32:35 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-03-18 09:30:00 | Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer

2019-03-12 10:30:08 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-03-05 08:30:00 | New Research: Key Drivers of Growth for American Tower Corporation REIT, Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production

2019-03-05 08:05:48 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-03-01 06:53:21 | Edited Transcript of CHRS earnings conference call or presentation 28-Feb-19 9:30pm GMT

2019-02-28 19:10:53 | Coherus BioSciences Inc CHRS Q4 2018 Earnings Conference Call Transcript

2019-02-28 16:30:00 | Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-26 09:30:00 | Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March

2019-02-22 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-02-14 09:30:00 | Coherus BioSciences to Report Fourth Quarter and Full Year 2018 Financial Results on February 28th

2019-02-11 14:46:00 | Here's Why Coherus BioSciences Rose 48.7% in January

2019-02-08 08:03:38 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-02-07 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-01-25 12:00:00 | Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation

2019-01-25 08:00:00 | Coherus BioSciences Announces Global Settlement with AbbVie Securing Rights to Commercialize its Adalimumab Biosimilar Candidate, CHS-1420

2019-01-18 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-01-17 08:04:10 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-01-15 11:03:51 | Coherus BioSciences, Inc. NASDAQ:CHRS Is Expected To Breakeven

2019-01-15 08:03:54 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-01-14 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2019-01-09 08:03:57 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2019-01-07 09:25:00 | Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners

2019-01-02 09:30:00 | Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference   

2018-12-22 08:02:21 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-12-20 08:02:25 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-12-19 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants

2018-12-18 08:02:35 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-12-12 00:13:14 | Should You Buy Coherus Biosciences Inc CHRS?

2018-12-06 08:02:34 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-12-03 07:40:00 | Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence

2018-11-30 09:30:00 | Coherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS

2018-11-29 07:52:12 | Coherus BioSciences CHRS: Moving Average Crossover Alert

2018-11-27 18:00:29 | Coherus BioSciences Announces New Employment Inducement Grants

2018-11-24 08:05:46 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-11-22 08:05:53 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-11-16 10:20:36 | Is Coherus BioSciences Inc’s NASDAQ:CHRS CEO Paid Enough Relative To Peers?

2018-11-15 08:05:47 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-11-12 08:05:46 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-11-12 08:00:00 | Coherus BioSciences Management to Present at the 27th Annual Credit Suisse Healthcare Conference

2018-11-09 08:04:51 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-11-09 05:17:06 | Edited Transcript of CHRS earnings conference call or presentation 8-Nov-18 9:30pm GMT

2018-11-08 17:03:38 | Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

2018-11-08 17:02:19 | Coherus BioSciences: 3Q Earnings Snapshot

2018-11-08 16:01:00 | Coherus BioSciences Reports Corporate Highlights and Third Quarter 2018 Financial Results

2018-11-06 08:03:41 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

2018-11-02 13:41:19 | U.S. FDA Approves UDENYCA™ pegfilgrastim-cbqv

2018-10-24 09:15:00 | New Research: Key Drivers of Growth for UnitedHealth Group, The Wendy's Co., Xenia Hotels & Resorts, TopBuild, Coherus BioSciences, and Virtu Financial — Factors of Influence, Major Initiatives and Sustained Production

2018-10-23 08:04:25 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.